STRO News and Press, Sutro Biopharma Inc. From 04/02/24

2024-04-02 06:36:56 ET More on Sutro Biopharma Ipsen secures exclusive global rights of Sutro Biopharma's STRO-003 ADC Seeking Alpha’s Quant Rating on Sutro Biopharma Historical earnings data for Sutro Biopharma Financial information for Sutro Biopharm...

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 14,4...

2024-04-02 04:03:00 ET Ipsen ( OTCPK:IPSEY ) has secured exclusive global rights for the development and commercialization of STRO-003, an antibody-drug conjugate, from Sutro Biopharma ( NASDAQ: STRO ), completing the final stages of pre-clinical development, the compa...

2024-03-27 08:24:20 ET More on premarket gainers & stock Veritone: Not An AI Stock To Bank On Veritone, Inc. (VERI) Q4 2023 Earnings Call Transcript Mesoblast Limited (MESO) Q2 2024 Earnings Call Transcript Mesoblast gains as FDA backs regulatory plans fo...

2024-03-26 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for STRO on March 26, 2024 06:07AM ET. The previous analyst recommendation was Buy. STRO was trading at $3.27 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...

2024-03-26 02:02:34 ET More on Sutro Biopharma Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement Seeking Alpha’s Quant Rating on Sutro Biopharma Historical earnings data for Sutro Biopharma Financial information for Sutro Biopharma ...

- Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple FolRα-expressing cancers - - Compelling anti-leukemic activity of luvelta in pediatric patients with relapsed/refractory CB...

2024-02-01 17:56:16 ET Gainers: Meta Platforms ( META ) +14% . Amazon ( AMZN ) +8% . Codexis ( CDXS ) +5% . Sutro Biopharma ( STRO ) +5% . Kulicke and Soffa Industries ( KLIC ) +5% . Losers: Atlassian Corporation ( TEAM...

2024-01-04 16:19:31 ET Gainers: Molecular Partners ( MOLN ) +14% . Sutro Biopharma ( STRO ) +9% . Ribbon Communications ( RBBN ) +7% . Resources Connection ( RGP ) +7% . Pyxis Oncology ( PYXS ) +6% . Losers: 89bio ( ETN...

Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer Potential benefit to 8 out of 10 platinum-resistant ovarian cancer patients, including addressing unmet need in patients with low-medium FolRα expression P...